Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy
Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy have?
Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy has 34 citations in the OpenAlex counts ScholarIQ stores.
When was Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy published?
Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy has 2024 year in the ScholarIQ index.
What is the open-access status of Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy?
Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy has closed oa status in the ScholarIQ index.
What is the DOI of Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy?
The DOI for Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy is on the source record.
What is the PMID of Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy?
The PMID for Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy is on the source record.
What is the OpenAlex record for Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy?
The OpenAlex for Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy is on the source record.